kidney semaglutide Ozempic picks up FDA indication to treat chronic disease The FDA just approved Ozempic

Strengthening protection can also encourage continued investment in advanced therapies such as monoclonal antibodies and gene therapies

In the multicenter PIVENS ( PI oglitazone versus V itamin E versus placebo for the treatment of N onalcoholic S teatohepatitis) trial, 247 subjects with MASH but not diabetes mellitus were randomized to receive 30 mg/day of pioglitazone (an insulin-sensitizing drug), 800 IU/day (536 mg/day) of RRR --tocopherol, or a placebo for 96 weeks (97)

Grellet A, Mila H, Heilmann RM, Feugier A, Gruetzner N, Suchodolski JS, et al

As of Monday, Eli Lilly had not yet responded to the findings, The Wall Street Journal said